… offer a new class of osteoporosis treatments, potentially with fewer side effects …

BOSTON, MA / ACCESS Newswire / July 31, 2025 / Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and …

… determining whether to initiate anti-osteoporosis treatment, supplement vitamin D, or adjust …

… substances can lower their efficacy. Osteoporosis medications: These should be avoided with …

… osteoporotic fracture and received subsequent osteoporosis treatment had a lower incidence of …

… 80 should be considered for osteoporosis treatment after a fracture to avoid … study supports the initiation of osteoporosis treatment after a fracture in people … didn't receive any osteoporosis treatments. Patients were followed for 5 …

… launch of denosumab biosimilars for osteoporosis treatment July 8, 2025 | Tuesday | News …

…  Yuyu Pharma’s long-selling osteoporosis drug Maxmarvil may help prevent bone …

SMC approval provides option for postmenopausal women at risk of fractures The Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women at very high risk of fracture through the NHS in …

… ‑head in South Korea’s osteoporosis treatment market after partnering with Hanmi … expertise, built through its oral osteoporosis drug RaboneD, which has led South … years. “As a powerhouse in osteoporosis treatment, we will strengthen our brand …